Artem Fedorinin

Dr. Artem Fedorinin

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
APAlyssa Pekonidi
Alyssa Pekonidi
NSNikita Sergeev
Nikita Sergeev
AFArtem Fedorinin
Artem Fedorinin
DLDmitry Laptev
Dmitry Laptev
MSMargarita Samsonova
Margarita Samsonova
NMNatalia G. Mokrysheva
Natalia G. Mokrysheva
Background: Type 1 diabetes mellitus (T1DM) is characterised by substantial heterogeneity in clinical manifestations, the rate of β-cell destruction, and diabetes-associated autoantibody (DAA) profiles across individuals of different ethnic backgrounds and ages. We investigated the immunological heterogeneity of T1DM through immunophenotyping of major lymphocyte populations using multiparameter flow cytometry. Results: T1DM associates with distinct immunophenotypes dependent on age, disease stage, DAA profiles, and the presence of Diabetic Ketoacidosis (DKA). Paediatric T1DM (n = 49) shows attenuated innate immunity (fewer NK and MAIT cells) alongside higher T-cell activation. Adult T1DM (n = 55) features remodelling in NK-cell receptor landscape, specifically expanding CD8+, CD38+, CD161+, and NKG2A+ NK-cell subsets. Long-standing T1DM (n = 28) combines higher CD8+ T-cell cytotoxicity with lower NK-cell cytotoxicity. High Autoantibody / Multi-antibody T1DM is marked by fewer CD8+ T cells, B cells, protective NKregs, and MAIT cells, but more CD38+ NK cells. Seronegative / Low Antibody T1DM shows a drop in total NK and NKeff cells, but an expansion of inhibitory, CD56bright, and CD8+ NK subsets. Paediatric DKA is linked to fewer innate-like T cells and more activated T cells. Adult DKA is characterized by drops in various NK cells (CD3-CD56+, CD3-CD8+, NKeff) and specific T cells (CD8+CD161+ and CD161+ double-negative). Conclusions: The immunological heterogeneity identified in patients with T1DM underscores the importance of patient stratification, which may facilitate the discovery of predictive and prognostic cellular biomarkers capable of estimating the rate of progression to clinically manifest T1DM and the risk of an aggressive disease course, respectively.